Search Results

CASI Pharmaceuticals, Inc. today reported financial results for the three months ended March 31, 2024.

CASI Pharmaceuticals, Inc. announced today the following: On April 12, 2024 CASI submitted the IND application to the FDA for CID-103 to support a phase 1/2 study of CID-103 in adults with chronic Immune Thrombocytopenia (ITP).

CASI Pharmaceuticals, Inc. reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas.

CASI Pharmaceuticals, Inc. announced that it has entered into securities purchase agreements with certain investors for a private investment in public equity financing that is expected to result in aggregate gross proceeds of approximately $15.0 million, before deducting placement agent fees and other private placement expenses.

CASI Pharmaceuticals, Inc. reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023.

CASI Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, announced that the Company is planning to submit an Investigational New Drug application to the U.S. Food and Drug Administration for CID-103 for the treatment of antibody-mediated rejection in kidney transplant recipients by the end of 2024.

CASI Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, proudly announced the administration of the first dose of FOLOTYN® to a patient in China.

CASI Pharmaceuticals Inc. is thrilled to announce a major milestone in its partnership with Juventas Cell Therapy Ltd. (Juventas).